Zacks Investment Research
30 Sept 2026, 18:50 UTC · 1h ago
Verdict
Headline takes no side. We score LQDA +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Liquidia has achieved four consecutive profitable quarters driven by sales of Yutrepia.
Priced inanalysis of previous quarters
So whatSustainable profitability reduces the likelihood of dilutive equity offerings to fund operations in FY2027.
More positive than 94% of claims this week
As of July 31, 2026, Liquidia had received approximately 5,900 unique prescriptions for Yutrepia.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced indata refers to July 31
So whatWith 30% of 1,100+ prescribing physicians writing for 5+ patients, the drug shows high prescriber loyalty early in its lifecycle.
More positive than 80% of claims this week
The FDA recently granted Fast Track designation to Yutrepia for an undisclosed additional indication.
Newtext states "recently granted"
More positive than 67% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company achieved its fourth consecutive profitable quarter driven by strong sales and positive prescription data for Yutrepia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
43m ago
−57.2%
Price is moving against the score
$30.26 vs $70.69 close before publication (Sep 29) · not market-adjusted
LQDA chart →
